"Mark Lebwohl, MD, Reviews Efficacy Of New Biologics For Psoriasis"
New biologics for psoriasis have achieved high levels of skin clearance in short-term and long-term trials that would’ve been unexpected a few years ago, according to a presentation at the American Academy of Dermatology Annual Meeting. Mark Lebwohl, MD, Sol and Clara Kest professor and chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, gave a presentation entitled “What’s New in Psoriasis?” There have been many recent biologic therapies developed for psoriasis, possibly because of one line in the Affordable Care Act that guarantees 12 years’ exclusivity for biologics. “These drugs have certainly been a blessing for our patients, [but] not such a blessing for our pocketbooks,” Dr. Lebwohl said
- Mark Lebwohl, MD, Professor, Chair, Dermatology, Icahn School of Medicine at Mount Sinai, System Chair, Dermatology, Mount Sinai Health System